Better Marijuana Stock to Buy Right Now: Tilray or Trulieve?

Trulieve became the first U.S. cannabis company listed on the NYSE under ticker TRUL on June 10, enabled by the U.S. rescheduling of medical marijuana. Trulieve reported $100 million in adjusted EBITDA in Q1 and turned a profit with EPS of $0.01, while Tilray expects EBITDA between $62 million and $72 million this year.